I attended Thursday's AGM online. All rather robotic. The...

I attended Thursday's AGM online. All rather robotic. The chairman read out his report, motions were voted on and shareholders invited to submit questions online of which there were none. All over in under 25 minutes.

On another note the Opthea website looks to have had a significant makeover albeit I hadn't looked at it for a while. Board membership has been updated etc but I not sure if the following guidance regarding trial timelines is current or just hasn't been updated.

Clearly the company is having an increasing focus on it's corporate direction.
Rather intriguing that the previous CFO Timothy Morris was replaced without as much as an acknowledgment by the company.

I think we are in for an interesting year in 2024

OPT-302 has the potential to become the first and only anti-VEGF-C / VEGF-D treatment for wet AMD and other retinal diseases. After meeting the primary endpoint in the Phase 2B wet AMD trial,⁹ the company is accelerating its late-stage clinical development of OPT-302 and has two ongoing Phase 3 clinical trials known as ShORe (OPT-302 + ranibizumab) and COAST (OPT-302 + aflibercept) that are each enrolling 990 treatment naïve patients with wet AMD.^10,11